Roche moves forward with injectable Actemra

Roche's ($RHHBY) bid to convert its leading biologic drugs to easy-to-use, subcutaneous injections just got another boost. The company's Genentech unit announced that Actemra, the rheumatoid arth…
Read the full story: News